This antibody, in combination with nivolumab as the PD-1 inhibitor, has been approved for the treatment of patients with metastatic colorectal cancer (CRC) with microsatellite instability-high (H-MSI) or mismatch repair (MMR) deficiencies [44]. Here, PDCD1 is linked to colorectal carcinoma.